pubmed.ncbi.nlm.nih.gov

Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer - PubMed

Affiliations

PMID: 26976997

Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer

Hyun-Ah Kim et al. Anticancer Res. 2016 Mar.

Abstract

Aim: We investigated whether the ovarian reserve determined on the basis of anti-Müllerian hormone (AMH) and inhibin B predicted disease-free survival (DFS) in premenopausal patients with hormone receptor-positive breast cancer treated with neoadjuvant chemotherapy.

Patients and methods: Our analysis included 32 premenopausal women with clinical stage III hormone receptor-positive invasive ductal breast cancer treated by neoadjuvant chemotherapy. Blood samples were obtained after neoadjuvant chemotherapy completion. The median follow-up period was 57.7 months.

Results: The median patient age was 41.5 years. The group with functional ovarian reserve was classified by higher AMH and higher inhibin B levels using cut-off values of 1,000 pg/ml and 30 pg/ml, respectively. The group with functional ovarian reserve had significantly worse DFS (p=0.043) than the group with ovarian failure.

Conclusion: The functional ovarian reserve defined by higher serum AMH and inhibin B after neoadjuvant chemotherapy predicted poor DFS in premenopausal women with clinical stage III hormone receptor-positive breast cancer.

Keywords: Breast neoplasms; anti-Müllerian hormone; estrogen receptor; inhibin B; ovarian function test.

PubMed Disclaimer

Cited by

Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery.
Kim HA, Choi J, Park CS, Seong MK, Hong SE, Kim JS, Park IC, Lee JK, Noh WC; The ASTRRA trial investigators. Kim HA, et al. Endocr Connect. 2018 Aug 1;7(8):949-956. doi: 10.1530/EC-18-0180. Endocr Connect. 2018. PMID: 30300533 Free PMC article.
Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.
Zhou B, Kwan B, Desai MJ, Nalawade V, Ruddy KJ, Nathan PC, Henk HJ, Murphy JD, Whitcomb BW, Su HI. Zhou B, et al. Fertil Steril. 2022 May;117(5):1047-1056. doi: 10.1016/j.fertnstert.2022.01.016. Epub 2022 Feb 23. Fertil Steril. 2022. PMID: 35216831 Free PMC article.
The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial.
Çelebi F, Ordu Ç, Ilgün S, Oztürk A, Erdoğan Iyigün Z, Alço G, Duymaz T, Aktepe F, Soybir G, Baysal B, Özmen V. Çelebi F, et al. Eur J Breast Health. 2020 Mar 17;16(3):177-182. doi: 10.5152/ejbh.2020.5114. eCollection 2020 Jul. Eur J Breast Health. 2020. PMID: 32656517 Free PMC article.
DDIT3 is associated with breast cancer prognosis and immune microenvironment: an integrative bioinformatic and immunohistochemical analysis.
Yu X, Li W, Sun S, Li J. Yu X, et al. J Cancer. 2024 May 28;15(12):3873-3889. doi: 10.7150/jca.96491. eCollection 2024. J Cancer. 2024. PMID: 38911383 Free PMC article.
Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR.
Pastore LM, Christianson MS, Stelling J, Kearns WG, Segars JH. Pastore LM, et al. J Assist Reprod Genet. 2018 Jan;35(1):17-23. doi: 10.1007/s10815-017-1058-4. Epub 2017 Oct 2. J Assist Reprod Genet. 2018. PMID: 28971280 Free PMC article. Review.

Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer - PubMed